The Host Capacity Model.

I. The problem with the dysbiosis-first paradigm

The dominant clinical narrative of chronic gut dysfunction places microbial composition at the center of the disease. Dysbiosis is treated as the lesion, and antimicrobial pressure — pharmaceutical or herbal — combined with prebiotic and probiotic re-seeding becomes the main intervention layer. This narrative is so embedded in both conventional gastroenterology and functional medicine that the question of whether it is descriptively correct is rarely asked.

HCM proposes that the microbial signature is better read as downstream of host state. That is a hypothesis about the direction of causation, and it is the central claim the framework asks to be tested.

The dysbiosis-first paradigm makes a specific empirical prediction. If the disease is the microbial composition, then correcting that composition should resolve the clinical picture. The prediction is testable, and it has been tested at scale — by gastroenterologists prescribing rifaximin, by functional clinicians cycling herbal antimicrobials, by patients running through elemental diets, and by a steadily expanding fecal microbiota transplant literature.

The reported pattern is inconsistent, and recurrence is common. SIBO recurs in a large share of treated cases. Dysbiosis returns within months of even aggressive treatment. The MCAS-like and post-infectious symptoms that travel with these conditions do not reliably resolve when the breath test normalizes. Patients move through years of careful work, accumulate diagnoses faster than treatments, and end up — six years and four specialists later — in roughly the position they began.

This pattern of failure is not a story about clinical incompetence. It is a story about a framework that treats the readout as the lesion. The microbial composition observed in chronic gut dysfunction is not the disease that produced it. It may represent an equilibrium state of a host substrate that has lost the capacity to maintain its own luminal environment. Until that substrate is addressed, no microbial intervention can hold against the equilibrium the host itself is producing.

The Host Capacity Model is the framework that organizes this re-reading. It begins from a different unit of analysis, makes different predictions, and points to a different set of interventions.

II. The substrate-first inversion

The thesis of the Host Capacity Model is direct. The microbial composition of the colon — and by extension the small bowel that interacts with it — is determined by the bioenergetic capacity of the host's epithelial cells, not the other way around. The dominant taxa in a healthy colon occupy their niche because the host is supplying the conditions that define that niche. When the host loses the capacity to supply those conditions, the niche collapses, the dominant taxa lose their advantage, and the community reorganizes around whatever metabolic conditions the compromised host actually produces.

This inverts the conventional sequence:

• The conventional sequence: dysbiosis (cause) → epithelial dysfunction (effect) → systemic illness (effect of effect)
• The HCM sequence: host capacity loss (cause) → epithelial bioenergetic failure (proximate mechanism) → microbial reorganization (readout) → systemic illness (cumulative consequence)

The implications of this inversion are substantial. If the conventional sequence is correct, the leverage point is microbial — change the bugs, fix the host. If the HCM sequence is correct, the leverage point is metabolic and bioenergetic — restore the host substrate, and the bugs reorganize around it.

Evidence establishes: antimicrobial and microbiome-directed interventions for recurrent SIBO and dysbiosis frequently show inconsistent, non-durable results in the published literature. HCM infers: this pattern is consistent with a substrate-level failure that microbial-only intervention does not address. Alternative explanations: the same pattern is equally consistent with motility disorders, reinfection, inadequate treatment duration, or heterogeneous patient populations being lumped together. Missing evidence: no study has directly compared substrate-first and microbe-first intervention arms. What would falsify this: consistent, durable resolution from antimicrobial therapy alone, without any substrate-directed work, in a well-characterized recurrent population.

III. Why the colonocyte

The unit of analysis in the Host Capacity Model is the colonocyte — the absorptive epithelial cell of the colon. The selection of this cell is not arbitrary. It rests on a set of well-characterized facts about colonocyte metabolism that, taken together, identify it as the load-bearing cell in the system.

Healthy colonocytes are obligate fatty-acid oxidizers. Unlike enterocytes of the small intestine, which derive most of their ATP from luminal glucose and amino acids, colonocytes draw 70–80% of their energy from the β-oxidation of butyrate, the four-carbon short-chain fatty acid produced by colonic anaerobic fermentation of dietary fiber. This is not a preference. It is a structural feature of colonocyte metabolism, conserved across mammalian biology, and the cell is metabolically configured for it.

The β-oxidation of butyrate is a high-rate, oxygen-consuming process. Each round of β-oxidation generates one FADH₂ and one NADH, which feed Complexes II and I respectively, drive the electron transport chain, and consume O₂ at Complex IV. The colonocyte is therefore a steep oxygen sink, and the apical surface of the colonic epithelium operates under near-anaerobic conditions because of the metabolic activity of the cell that produces it. This is physiological hypoxia — and it is the precondition for the dominant healthy microbial community.

Physiological hypoxia at the epithelial surface is what allows obligate anaerobes to dominate the colonic lumen. Faecalibacterium prausnitzii, Eubacterium rectale, Roseburia intestinalis, the Lachnospiraceae and Ruminococcaceae more broadly — the taxa most consistently associated with metabolic, immunological, and barrier health — are obligate anaerobes that cannot survive at meaningful oxygen concentrations. The healthy colonic environment is hospitable to them precisely because the colonocytes are consuming the oxygen at the surface. The community that defines a healthy gut is, in this sense, built by the host.

The reverse is also true. When colonocyte oxidative metabolism falters and the cell shifts to glycolysis (the Warburg-like shift), oxygen is no longer consumed at the rate required to maintain hypoxia. Oxygen leaks into the lumen. The obligate anaerobes lose their niche. Facultative anaerobes — particularly the Enterobacteriaceae (E. coli, Klebsiella, Citrobacter, Salmonella) — expand into the new aerobic-tolerant environment. This is not speculation; it is the substance of an established line of work in microbial ecology, developed substantially in the Andreas Bäumler lab (Litvak et al., Byndloss et al.) and corroborated across multiple animal and human models of colitis, post-antibiotic dysbiosis, and inflammatory bowel disease.

The colonocyte is therefore the load-bearing cell because it is the cell whose metabolism defines the niche in which the healthy microbial community lives. Failures elsewhere in the system — small intestinal enterocyte dysfunction, hepatic dysfunction, immune dysregulation — matter, but they do not directly determine the colonic environment. The colonocyte does. If the colonocyte fails, the rest follows.

IV. The three pillars of colonocyte capacity

For a colonocyte to oxidize butyrate at the rate required to maintain epithelial hypoxia, three independent requirements must be met. Each is a potential point of failure. The Host Capacity Model treats them as the three pillars of colonocyte capacity, and the loss of any one is sufficient to compromise the system.

Pillar 1: Substrate transport — SLC5A8 and the butyrate uptake problem

Butyrate produced in the lumen must enter the colonocyte before it can be oxidized. The principal apical transporter is SLC5A8 — the sodium-coupled monocarboxylate transporter (SMCT1) — a high-affinity, sodium-dependent uptake protein expressed at the brush border of differentiated colonocytes. A secondary route is SLC16A1 (MCT1), a proton-coupled, lower-affinity transporter that operates predominantly basolaterally.

SLC5A8 is also a tumor suppressor gene. Its expression is reduced or absent in colorectal carcinoma — a finding that reflects the broader fact that SLC5A8 is epigenetically regulated, and its promoter is silenced by CpG methylation under conditions of chronic inflammation and the early stages of neoplastic transformation. The relevance to chronic illness is direct. Sustained mucosal inflammation — whether driven by infection, post-infectious immune activation, food antigen exposure across a compromised barrier, or low-grade endotoxemia — produces the methylation environment that drives SLC5A8 silencing.

The functional consequence is that the colonocyte loses its primary route for butyrate uptake even when colonic butyrate production is preserved. This decoupling — adequate luminal butyrate, inadequate intracellular butyrate — is one of the key clinical paradoxes the HCM resolves. Patients with measurable butyrate-producing taxa on stool testing, and even patients on high-dose butyrate supplementation, can fail to access the substrate at the cellular level because the transport infrastructure has been silenced.

The reversibility of SLC5A8 silencing is partial and slow. Promoter demethylation does occur, particularly when the inflammatory drive that produced the silencing is removed, but the timescale is months, not days. This is one of the reasons HCM-anchored work is patient with timeline expectations.

Pillar 2: Mitochondrial machinery — iron-sulfur clusters, β-oxidation, and the electron transport chain

Once butyrate enters the colonocyte, its oxidation depends on intact mitochondrial machinery. The β-oxidation pathway itself requires acyl-CoA dehydrogenases (LCAD, MCAD, SCAD), enoyl-CoA hydratases, hydroxyacyl-CoA dehydrogenases, and thiolases — none of which are limiting in most clinical contexts. The limiting machinery is downstream: the electron transport chain that accepts the reducing equivalents β-oxidation produces.

The electron transport chain is built around iron-sulfur (Fe-S) cluster proteins. Complex I (NADH:ubiquinone oxidoreductase) contains eight Fe-S clusters distributed across its iron-protein subunits. Complex II (succinate dehydrogenase) contains three Fe-S clusters in its SDHB subunit. Complex III (cytochrome bc₁) contains the Rieske Fe-S protein. Aconitase, a TCA cycle enzyme that is itself essential for the citrate-to-isocitrate step that feeds NADH and FADH₂ generation, is a cytosolic and mitochondrial Fe-S protein. The system depends on the integrity of dozens of Fe-S clusters distributed across the matrix and inner membrane.

Iron-sulfur cluster biogenesis is a tightly regulated process involving cysteine desulfurase (NFS1), the scaffold protein ISCU, and frataxin (FXN) — the protein whose loss produces Friedreich's ataxia, a disease whose phenotype is, instructively, dominated by mitochondrial dysfunction in the most metabolically demanding tissues of the body. Fe-S cluster biogenesis is not a one-time event; clusters are continuously damaged by reactive species and continuously remade. The biogenesis machinery requires reduced cysteine substrate, intact frataxin, an iron pool that is bioavailable but not redox-active in damaging concentrations, and a redox environment that does not exceed the cell's repair capacity.

Two specific failure modes dominate in chronic illness. Oxidative damage to existing Fe-S clusters — particularly from peroxynitrite, the product of nitric oxide and superoxide that accumulates during inflammation — destroys clusters faster than the biogenesis machinery can rebuild them. Substrate depletion for cluster biogenesis — particularly NAD⁺ depletion (since NAD⁺ is required for the redox biochemistry of cluster assembly) and cysteine depletion (since chronic inflammation diverts cysteine to glutathione synthesis, depleting the substrate available for NFS1) — slows the biogenesis rate even when the machinery itself is intact.

Either failure mode produces a colonocyte whose electron transport chain is operating well below capacity. Butyrate that enters the cell encounters β-oxidation machinery that cannot dispose of the reducing equivalents it generates. The TCA cycle backs up. NADH/NAD⁺ ratios shift. The cell shifts to glycolysis as the dominant ATP source. Oxygen consumption falls. Physiological hypoxia is lost.

Pillar 3: Regulatory integrity — SIRT3, NAD⁺, and acetylation control of the matrix proteome

The third pillar is the regulatory layer that determines whether the metabolic machinery, even when structurally intact, operates at the right rate and in the right direction.

SIRT3 is the dominant mitochondrial NAD⁺-dependent deacetylase. Its substrates include long-chain acyl-CoA dehydrogenase (LCAD, controlling β-oxidation rate), succinate dehydrogenase (SDHA, controlling Complex II activity), isocitrate dehydrogenase (IDH2, controlling TCA flux and NADPH generation), glutamate dehydrogenase (GDH), ornithine transcarbamylase (OTC, controlling urea cycle handling of ammonia load), and manganese superoxide dismutase (SOD2, controlling matrix antioxidant defense). SIRT3 maintains these substrates in a deacetylated, catalytically competent state.

SIRT3 activity depends on NAD⁺. Its catalytic mechanism consumes NAD⁺ stoichiometrically, generating O-acetyl-ADP-ribose and nicotinamide. When matrix NAD⁺ falls, SIRT3 activity falls in direct proportion. Substrate hyperacetylation accumulates. Each of the hyperacetylated enzymes operates at reduced rate, with distorted kinetics, and often with altered allosteric regulation.

The aggregate effect of SIRT3 disabling is a hyperacetylated matrix proteome — a recognizable biochemical signature in which dozens of metabolic enzymes are simultaneously partially impaired. This is the molecular substrate of what is clinically described as "mitochondrial dysfunction" in patients without primary mitochondrial mutations. The mitochondria are intact. Their regulation is broken. The cell has the proteins, the structures, the substrates, but it has lost the cofactor that maintains the proteome in its active state.

The NAD⁺ pool that supplies SIRT3 is not unlimited. It is the product of biosynthesis (de novo from tryptophan, salvage from nicotinamide via NAMPT, and direct uptake of precursors like NMN and NR) minus consumption (by SIRT3 and the other sirtuins, by PARP enzymes during DNA damage repair, and — most consequentially in chronic illness — by CD38).

This is the entry point for the first dominant upstream insult.

V. The two dominant upstream insults

Two failure modes are proposed as the dominant upstream insults within this framework. No prevalence claim is made: BiomeLogic has not measured how often either appears, and the distribution across any real population is unknown. Identifying which is more plausible in a given case is a substantial part of the analysis work.

A. The CD38–NAD⁺–SIRT3 cascade

CD38 is a plasma membrane glycoprotein with NAD⁺ glycohydrolase (NADase) activity. Its catalytic turnover number for NAD⁺ is two to three orders of magnitude higher than the sirtuins or PARPs. At baseline expression — the resting state in healthy tissue — CD38 is a modest contributor to NAD⁺ metabolism. At inflammation-induced expression, it dominates.

CD38 is strongly upregulated by:

• Type-I interferons (IFN-α and IFN-β) — the principal inflammatory output of viral and post-viral immune activation, which is why CD38 expression rises sharply after SARS-CoV-2 infection, EBV reactivation, and other viral triggers
• Lipopolysaccharide (LPS) — the principal output of barrier failure and endotoxemia, which is why CD38 expression tracks gut permeability in the absence of any acute infection
• TNF-α and IL-6 — the cytokines of chronic low-grade inflammation
• Senescence-associated secretory phenotype (SASP) signaling — the inflammatory output of aging tissues, which is why CD38 expression rises measurably with age and is one of the best-characterized molecular drivers of the age-associated NAD⁺ decline

The induction can be substantial. In aged tissue, CD38 expression rises 5- to 10-fold. In post-COVID tissue, similar increases have been documented. The NAD⁺ pool collapses in the cells where CD38 is most strongly upregulated, because salvage synthesis through NAMPT cannot keep pace with the increased turnover.

This is not a hypothetical mechanism. The Eduardo Chini laboratory at Mayo Clinic, the David Sinclair group at Harvard, and a number of independent investigators have established the CD38-NAD⁺ relationship in detail. CD38 knockout mice are protected from the age-associated NAD⁺ decline. CD38 inhibitors restore NAD⁺ in aged and inflamed tissue. The cascade is biochemically validated.

The downstream consequences in the colonocyte follow the structure described in Pillar 3. NAD⁺ depletion disables SIRT3. SIRT3 disabling produces a hyperacetylated matrix proteome. The hyperacetylated proteome operates at reduced rate across β-oxidation, the TCA cycle, the electron transport chain, and the urea cycle. The cell's bioenergetic output falls. Oxygen consumption falls. Epithelial hypoxia is lost.

The cascade is not contained at the colonocyte. CD38 is systemically upregulated by systemic inflammatory drive. The same NAD⁺ depletion that compromises colonocyte function compromises mitochondrial function in skeletal muscle (producing the exercise intolerance and post-exertional malaise of long-haul illness), in the central nervous system (producing the cognitive features), in the ovary (producing the fertility ceiling), and in cardiac tissue (producing the dysautonomic features). What presents clinically as a multi-system disease is, under this framework, a proposed convergent expression of one substrate failure across tissues — an HCM inference, not an established finding. Alternative explanations include independent tissue-specific pathologies that merely co-occur.

B. SLC5A8 epigenetic silencing

The second dominant insult operates at the substrate-supply level rather than the cofactor level. Sustained mucosal inflammation drives DNMT-mediated CpG methylation of the SLC5A8 promoter region, silencing transcription of the colonocyte's principal butyrate uptake transporter. The cell continues to express the rest of the β-oxidation machinery, but it cannot acquire the substrate.

Several features of SLC5A8 silencing make it particularly relevant to chronic illness:

It is bidirectionally linked to the CD38 cascade. The inflammation that drives SLC5A8 methylation also drives CD38 induction. The cell loses both substrate access and cofactor availability simultaneously. This co-occurrence is an observed pattern in HCM-reviewed cases, not a quantified finding; BiomeLogic has not measured its frequency in any defined population.

It is partially reversible but on a slow timescale. Demethylation of the SLC5A8 promoter does occur when the inflammatory drive is removed, but the timescale is months. This is one of the reasons HCM-anchored interventions take months rather than weeks to express their full effect.

It is invisible on standard testing. No commercially available test directly measures SLC5A8 expression or methylation status in human colonocytes. The lesion is inferred from clinical pattern: butyrate-producing taxa preserved or increased on stool testing, butyrate supplementation producing minimal benefit, and the broader signature of HCM-pattern dysfunction. Direct measurement would require colonic biopsy with immunohistochemistry or methylation analysis — research-grade, not clinical-grade, work.

It explains the limited response to high-dose butyrate supplementation in this patient population. This is one of the model's clearer predictions. Patients with intact SLC5A8 expression respond well to colonic butyrate. Patients with silenced SLC5A8 do not, because the substrate cannot enter the cell. The clinical heterogeneity in butyrate-supplementation response, which has produced an unsatisfying literature, is — under the HCM lens — exactly what the model would predict.

VI. Downstream consequences

When the upstream insults are present, the colonocyte loses bioenergetic capacity. The downstream consequences follow with predictable regularity. Each one is a distinct mechanism. Each one is partially independent of the others, but they reinforce one another, and the clinical picture is the cumulative effect.

Loss of physiological hypoxia and microbial reorganization

The first and most direct consequence is the loss of epithelial hypoxia. Colonocyte oxygen consumption falls. Oxygen leaks into the lumen. The obligate anaerobic core community — the Faecalibacterium, Roseburia, Eubacterium taxa — loses its competitive advantage. Facultative anaerobes — the Enterobacteriaceae, particularly E. coli and Klebsiella, and in some patients the sulfate-reducing taxa discussed below — expand into the open niche.

This is dysbiosis, viewed correctly. It is not a primary microbial disease. It is the readout of a host substrate that has lost the capacity to define its own niche. The microbial composition changes because the conditions that maintained the previous composition no longer exist.

This explains, among other things, why fecal microbiota transplantation produces inconsistent results in chronic gut disease. Transplanting a healthy donor community into a recipient whose host substrate cannot maintain that community produces a transient improvement followed by reversion to the recipient's underlying equilibrium. The community goes back to what the host is selecting for. The lesson is not that FMT does not work; it is that FMT cannot work without addressing the substrate that determines the equilibrium state.

H₂S Complex IV poisoning and the recurrence loop

When the displaced community is dominated by sulfate-reducing taxa — Desulfovibrio piger most prominently in the human colon, with Bilophila wadsworthia and several related organisms contributing — the metabolic byproduct is hydrogen sulfide. At low concentrations H₂S is a signaling molecule with vasodilatory, anti-inflammatory, and cytoprotective effects. At sustained high concentrations, it is a respiratory toxin.

The relevant respiratory toxicity is direct inhibition of cytochrome c oxidase — Complex IV of the electron transport chain. H₂S binds the heme iron in the active site of cytochrome c oxidase and competitively inhibits oxygen reduction. Complex IV is the terminal step of mitochondrial electron transport; when it is inhibited, the upstream complexes back up, electron flow stalls, ATP synthesis falls, and the cell shifts further toward glycolysis. The colonocyte that was already struggling to oxidize butyrate now cannot perform oxidative phosphorylation either.

This produces the recurrence loop that is the most distinctive feature of H₂S SIBO. The bioenergetic lesion that allowed sulfate-reducers to expand has been deepened by the metabolic byproduct of their expansion. Antimicrobial treatment reduces the H₂S-producing population. H₂S concentrations fall. Complex IV inhibition lifts. Colonocyte oxidative metabolism partially recovers. But the underlying substrate failure was never addressed. As antimicrobial pressure ends, the niche reopens, the sulfate-reducers expand back into it, H₂S production returns, Complex IV inhibition returns, and the cycle resumes.

This is why standard SIBO recurrence is not a story about resistance, reinfection, or prokinetic insufficiency. It is a story about the equilibrium state of a substrate that has not been restored. Treating the microbes alone treats one half of a feedback loop and leaves the other half running.

Intestinal alkaline phosphatase failure

Intestinal alkaline phosphatase (IAP) is a brush-border enzyme produced by the enterocytes of the small intestine and to a lesser extent the colonocytes. Its principal function in the context of HCM is dephosphorylation of bacterial lipopolysaccharide. Dephosphorylated LPS is a markedly weaker TLR4 agonist than its phosphorylated form. Functional IAP is therefore a major determinant of how much pro-inflammatory signaling LPS produces as it crosses the epithelium.

IAP secretion depends on enterocyte energetic capacity. As capacity falls, IAP secretion falls. LPS detoxification at the brush border becomes inadequate. The LPS that crosses a compromised barrier reaches systemic circulation in its more pro-inflammatory form and at higher concentrations than it would have in a healthy gut. The result is low-grade endotoxemia — measurable by elevated LBP, CD14, and serum LPS in patients with HCM-pattern presentations even in the absence of acute infection.

The endotoxemia drives the systemic inflammatory tone that, in turn, drives CD38 induction. The loop closes.

This is one of the more important features of the model: HCM is not a linear cascade. It is a self-reinforcing circuit. The substrate failure produces the inflammatory drive that worsens the substrate failure. Without intervention, the system finds its own equilibrium, and the equilibrium is the disease state the patient presents with.

Cholinergic anti-inflammatory pathway collapse

The vagus nerve provides the principal parasympathetic innervation of the gut and one of the principal anti-inflammatory regulatory inputs to the immune system. Vagal afferent fibers detect inflammatory signals in the gut wall and relay them to the brainstem. Vagal efferent fibers, signaling through acetylcholine acting on the α7 nicotinic acetylcholine receptor (α7nAChR) on tissue macrophages and mast cells, suppress cytokine release and degranulation. This is the "cholinergic anti-inflammatory pathway" or "inflammatory reflex," characterized substantially in the Kevin Tracey laboratory.

Vagal afferent function depends on the integrity of the enteric environment that produces the signals it carries. When the gut substrate is compromised, vagal afferent signaling is degraded, the brainstem regulation that depends on it is compromised, and vagal efferent output to the periphery falls. The α7nAChR-mediated brake on inflammation is lifted. Tissue mast cells become hyperreactive to ordinary stimuli that would otherwise be tolerated. Macrophage cytokine release is disinhibited. Sympathovagal balance shifts toward sympathetic dominance.

The clinical signature of this failure is recognizable: orthostatic intolerance and postural symptoms, sleep disturbance with predominance of light-sleep architecture, episodic flares triggered by emotional or thermal stress, reduced heart rate variability, and the autonomic features that travel with hEDS, POTS, and a substantial fraction of post-viral illness. Heart rate variability — measurable noninvasively — is one of the better surrogate markers of vagal tone in this population.

Mast cell activation pattern shift

The combination of antigen flux across a compromised barrier (Pillar 1 and 2 substrate failure), low-grade endotoxemia (IAP failure), vagal withdrawal (cholinergic anti-inflammatory pathway collapse), and chronic inflammatory drive (CD38 induction's cause and effect) produces the clinical constellation recognized as mast cell activation syndrome.

But MCAS, viewed through the HCM lens, is not a single mechanism. It is at least four mechanistically distinct patterns that share a surface presentation:

• Pattern A — barrier-driven: continuous antigen exposure through a compromised mucosal barrier produces near-continuous mast cell activation. GI-predominant presentation. Postprandial flushing. Strong response to elimination diets.
• Pattern B — neuroimmune (vagal): loss of α7nAChR-mediated brake on mast cell activation. Autonomic-predominant presentation. Postural and stress-triggered flares. Often co-occurring with hEDS and POTS.
• Pattern C — chemical/toxicant: direct activation of mast cells by environmental triggers — fragrances, mycotoxins, heavy metals, certain pharmaceuticals. Exposure-correlated presentation. Patients can identify specific triggers with high consistency.
• Pattern D — clonal/KIT-driven: intrinsic mast cell activation independent of upstream signal. True monoclonal mast cell activation syndrome and the systemic mastocytoses. Hematologic disease, distinct from the other three.

The first three patterns are downstream consequences of HCM. Pattern D is not. The clinical relevance of the stratification is that the interventions are not interchangeable. Pattern A responds to barrier work. Pattern B responds to autonomic work. Pattern C responds to load reduction. Pattern D requires hematology-grade care. A generic MCAS protocol applied across the four patterns produces the inconsistent literature and the inconsistent clinical results that have characterized MCAS work for the past decade.

Systemic mitochondrial spillover

The CD38 induction that initiates the cascade in the gut is not gut-specific. The same inflammatory signals that upregulate CD38 in colonocyte tissue upregulate it systemically. Skeletal muscle, central nervous system, ovarian granulosa, cardiac tissue, hepatic tissue — all show elevated CD38 in response to the same inflammatory drive that produced the gut lesion. NAD⁺ depletion follows. SIRT3 disabling follows. Tissue-specific clinical signatures follow.

This is why HCM is not a gut-only model. The fatigue, post-exertional malaise, cognitive dysfunction, exercise intolerance, fertility ceiling, and slow recovery from stressors that travel with chronic illness may, under this framework, reflect convergent expression of one substrate failure rather than six unrelated conditions. That reading is an HCM inference, not an established finding: the alternative — genuinely independent, co-occurring conditions — has not been ruled out, and no data currently distinguishes the two possibilities.

VII. The clinical phenotypes re-read

The framework's leverage comes from applying it to specific clinical phenotypes. Each of the following is a case where the HCM provides a more parsimonious account of the data than the conventional model.

Recurrent SIBO

Conventional model: SIBO is a small intestinal disorder of microbial overgrowth treated by antimicrobial reduction. Recurrence is attributed to motility failure, anatomical predisposition, antimicrobial resistance, or insufficient duration of treatment.

HCM re-read: SIBO is a downstream consequence of colonic substrate failure that allows facultative anaerobes to expand into the cecal and ileocecal region. The small intestinal overgrowth is read, under this framework, as a sentinel — the recurrence may reflect an equilibrium state of a colonic substrate that has not been restored. HCM infers that antimicrobial intervention alone is working against the host's own microbial selection. This is a prediction, not a demonstrated result: BiomeLogic has not measured recurrence rates in any defined population, and documented recurrence after antimicrobial therapy has several competing explanations, including motility failure and reinfection.

Mast cell activation syndrome

Conventional model: MCAS is a primary mast cell disorder treated by mast cell stabilization.

HCM re-read: HCM proposes that a portion of MCAS-labelled presentations may be Patterns A through C — potentially downstream of barrier failure, vagal withdrawal, or load-driven activation. No proportion is claimed. Pattern D is primary mast cell disease and belongs to a different specialty. The framework predicts, untested, that outcomes differ between pattern-matched and unmatched approaches. That prediction has not been tested and BiomeLogic makes no claim about improvement.

Post-viral and long-haul illness

Conventional model: post-viral syndrome is poorly characterized and often grouped under "post-acute sequelae" without specific mechanism.

HCM re-read: post-viral immune activation drives CD38 induction. CD38 induction depletes NAD⁺ systemically. NAD⁺ depletion compromises SIRT3-dependent mitochondrial regulation. The compromise expresses in the tissues that are most metabolically demanding — colonocyte, skeletal muscle, central nervous system, autonomic regulation. The clinical signature that travels with long-haul illness — fatigue, post-exertional malaise, cognitive features, autonomic instability, gut symptoms, mast cell features — is the predicted pattern.

hEDS / POTS / MCAS overlap

Evidence establishes: hEDS, POTS, and MCAS co-occur in clinical populations at rates higher than chance, and hEDS-associated connective tissue changes are associated with increased gut permeability in some studies.

HCM infers: that the three may share a common downstream pathway — barrier compromise feeding antigen flux and Pattern A mast cell activation, with chronic inflammation contributing to CD38 induction and the autonomic features associated with POTS. This is offered as one possible reading, not a demonstrated causal chain.

Alternative explanations: the three conditions may reflect a shared genetic predisposition acting on multiple systems independently and in parallel, with no sequential or causal relationship between them at all.

Missing evidence: no longitudinal study has tracked barrier status, CD38 expression, and autonomic function together in a defined hEDS cohort to test whether the proposed sequence actually occurs in that order. What would falsify this: POTS or MCAS onset preceding any measurable barrier or inflammatory change would weigh against a barrier-first sequence.

The fertility ceiling

Conventional model: age-related fertility decline is a function of decreasing oocyte quality of unspecified mechanism.

HCM re-read: oocyte mitochondrial competence is set during the ~90-day folliculogenesis window, and the somatic cell environment that supports the oocyte is the determinant of mitochondrial output. Systemic CD38 induction and NAD⁺ depletion compromise the granulosa cell environment, which in turn compromises oocyte mitochondrial biogenesis during the developmental window. Whether this has any bearing on fertility outcomes is unknown and untested. BiomeLogic makes no fertility claim, offers no fertility protocol, and does not work in reproductive medicine. This section is included only because the framework generates the question, not because it answers it.

ME/CFS-pattern fatigue

Conventional model: ME/CFS is a poorly characterized fatigue syndrome of disputed etiology.

HCM re-read: chronic CD38-driven mitochondrial dysfunction, expressed predominantly in skeletal muscle and central nervous system, produces the post-exertional malaise, exercise intolerance, and cognitive features that define ME/CFS. The metabolic phenotyping work that has emerged in this field — impaired aerobic capacity, abnormal lactate handling, post-exertional metabolic flare — is consistent with the model's predictions. Whether any ME/CFS is HCM-pattern is unresolved, and no treatment claim is made or implied.

VIII. What the framework predicts

A framework’s value is in the predictions it produces and in how it could be shown wrong. Everything below is an untested prediction. None of it is presented as a result.

Recurrence-without-substrate-restoration. Antimicrobial intervention without HCM substrate work produces predictable recurrence. This is the framework’s most easily falsified prediction: consistent durable remission after antimicrobial therapy alone would weigh against it.

Pattern-specific MCAS response. The four MCAS patterns respond differentially to pattern-specific interventions. A formal trial in stratified MCAS populations would test this directly. The current literature's inconsistency is, under the model, an artifact of unstratified populations.

Substrate-restoration kinetics. The framework predicts that any change tied to biogenesis and epigenetic remodelling would be slow rather than immediate. No timeline is claimed, because none has been measured.

Concurrent improvement across end-organ systems. When HCM-anchored work succeeds, gains appear across gut, autonomic, immune, and energetic systems concurrently — not sequentially. Patchy or system-restricted response is a sign that the dominant mechanism is not HCM-pattern in that case.

The folliculogenesis window. If somatic-cell bioenergetics matter to oocyte competence, timing effects should be observable within the folliculogenesis window and absent outside it. This is a research question only; BiomeLogic makes no fertility claim.

The systemic NAD⁺ correlate. Patients with HCM-pattern clinical presentations should show evidence of systemic NAD⁺ depletion — measurable in tissue compartments where it can be assessed, inferable from response to NAD⁺ precursor supplementation, and consistent with the inflammatory markers that drive CD38 induction.

The framework is therefore not vague: it produces claims that can fail. As of this version, none of these predictions has been formally tested, and BiomeLogic holds no outcome data that would support them.

IX. Why this framework differs from existing models

Several existing frameworks address subsets of the territory the HCM covers. The HCM is not a wholesale rejection of these. It is a more parsimonious organizing structure that absorbs what each gets right and resolves the contradictions between them.

vs. the dysbiosis-first paradigm. The HCM accepts that microbial composition matters. It rejects the claim that microbial composition is the primary lesion. The order of causation is reversed.

vs. functional medicine "leaky gut" framing. Increased intestinal permeability is real and matters, but it is a downstream readout of substrate failure, not the candidate upstream mechanism. Treating the barrier without addressing the substrate that maintains it produces transient improvement.

vs. pure mitochondrial dysfunction frameworks. Mitochondrial dysfunction is central to the HCM. The HCM's contribution is identifying the regulatory cascade — CD38–NAD⁺–SIRT3 — that produces functional mitochondrial dysfunction in patients without primary mitochondrial mutations, and identifying the colonocyte as the load-bearing site where this cascade becomes clinically dominant.

vs. pure mast cell models. Mast cell activation is a real mechanism in the HCM. The HCM's contribution is stratifying it into mechanistically distinct patterns and identifying the upstream drivers that produce three of those four patterns.

vs. autoimmune-first models. Many HCM-pattern presentations carry autoimmune markers. The HCM does not deny this. It proposes that, in many cases, the autoimmunity is a downstream consequence of barrier failure and chronic inflammatory drive, rather than a primary autoimmune disease that happens to present with gut and energetic features.

The HCM is not the first framework to identify any of these mechanisms individually. Its contribution is the integration.

X. The limits of the model

A framework's credibility depends on its willingness to specify what it does not explain.

The HCM does not yet adequately account for:

• Heavy metal and mycotoxin load as primary drivers in cases where these are dominant. The framework can absorb them as drivers of inflammation that feed the cascade, but in some patients they are the principal lesion and the gut substrate is downstream.
• Specific genetic variants that modulate the picture in ways still being mapped. MTHFR, COMT, MTRR, FUT2 secretor status, HLA variants associated with autoimmune predisposition, and others change the kinetics and the intervention response in ways the current framework only partially predicts.
• Tick-borne and chronic infectious drivers in cases where ongoing infection is the principal driver of the inflammation that drives the cascade. The framework treats these as upstream amplifiers, but the clinical work in such cases requires infectious-disease-grade evaluation that the HCM does not replace.
• Primary endocrine disease — particularly thyroid pathology, adrenal disease, and pituitary disease — which can produce overlapping phenotypes through different mechanisms.
• Trauma, psychosocial factors, and nervous system dysregulation that extends beyond the cholinergic anti-inflammatory pathway. These matter, the framework engages with them where they intersect with vagal regulation, but the broader autonomic and limbic territory is not fully integrated.

Where these factors are dominant, the framework hands off. The work then belongs to specialists in those domains, with the HCM perspective offered as one of several inputs rather than the organizing principle.

The framework is, in this sense, a work in progress. Its current scope is what the current evidence supports.

XI. How this framework is used in practice

A consultation anchored in the Host Capacity Model is, at its core, a re-reading of the case against this framework: identifying which arm of the proposed substrate failure may be relevant to a given host, and where the testing data already collected does or does not fit the pattern.

The output is a written mechanistic summary for the client and their licensed medical team to evaluate. BiomeLogic does not prescribe, diagnose, or sequence treatment, and makes no claim about response timelines, intervention order, or expected outcomes. No intervention protocol, supplement sequence, or timeline is offered on this page or implied by the framework.

XII. Closing

The Host Capacity Model is the framework that organizes the consulting work at BiomeLogic. It is also the framework that organizes the publishing work — each long-form essay on the site develops one mechanism within the model in detail. The framework is not finished. Its predictions are stated so that they can be tested, and the falsifiability criteria below set out what would count as evidence against the model. No clinical trial of the model has been conducted, and BiomeLogic holds no institutional or research affiliation.

For readers new to the framework, the recommended entry sequence is available in the articles:

1. The Host Capacity Model: an introduction
2. The CD38–NAD⁺–SIRT3 cascade in chronic illness
3. H₂S Complex IV poisoning in recurrent SIBO
4. Stratifying MCAS
5. Case reasoning: a long-haul presentation

Questions, corrections, or critique of the framework can be sent to research@biomelogic.net. This is a correspondence address, not a claim of formal academic review or institutional collaboration.

BiomeLogic does not provide clinical care. Mohammed Attallah is not a licensed clinician. The framework above is intended for educational and research purposes and is delivered, in consultation, in coordination with the client's licensed medical team. See the Scope of Practice.